CUE Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -259.59% compared to Cue Biopharma's net margin of 14.23%. Cue Biopharma's return on equity of -142.28% beat Biomarin Pharmaceutical's return on equity of 6.29%.

Cue Biopharma has a consensus price target of $4.20, signalling upside risk potential of 246.15%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 46.63%. Given that Cue Biopharma has higher upside potential than Biomarin Pharmaceutical, analysts believe Cue Biopharma is more attractive than Biomarin Pharmaceutical.

Cue Biopharma has a beta of 1.658, which suggesting that the stock is 65.823% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.

Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Cue Biopharma quarterly revenues are $3.3M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. Cue Biopharma's net income of -$8.7M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, Cue Biopharma's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 40.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 5.40x versus 4.77x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Cidara Therapeutics has a net margin of -259.59% compared to Cue Biopharma's net margin of -30201.66%. Cue Biopharma's return on equity of -142.28% beat Cidara Therapeutics's return on equity of -443.37%.

Cue Biopharma has a consensus price target of $4.20, signalling upside risk potential of 246.15%. On the other hand Cidara Therapeutics has an analysts' consensus of -- which suggests that it could grow by 22.42%. Given that Cue Biopharma has higher upside potential than Cidara Therapeutics, analysts believe Cue Biopharma is more attractive than Cidara Therapeutics.

Cue Biopharma has a beta of 1.658, which suggesting that the stock is 65.823% more volatile than S&P 500. In comparison Cidara Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.883%.

Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. Cidara Therapeutics pays out -- of its earnings as a dividend.

Cue Biopharma quarterly revenues are $3.3M, which are larger than Cidara Therapeutics quarterly revenues of $302K. Cue Biopharma's net income of -$8.7M is higher than Cidara Therapeutics's net income of -$16M. Notably, Cue Biopharma's price-to-earnings ratio is -- while Cidara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 5.40x versus 1.95x for Cidara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

FibroGen has a net margin of -259.59% compared to Cue Biopharma's net margin of -36.87%. Cue Biopharma's return on equity of -142.28% beat FibroGen's return on equity of --.

Cue Biopharma has a consensus price target of $4.20, signalling upside risk potential of 246.15%. On the other hand FibroGen has an analysts' consensus of $10.00 which suggests that it could grow by 1624.14%. Given that FibroGen has higher upside potential than Cue Biopharma, analysts believe FibroGen is more attractive than Cue Biopharma.

Cue Biopharma has a beta of 1.658, which suggesting that the stock is 65.823% more volatile than S&P 500. In comparison FibroGen has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.658%.

Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. FibroGen pays out -- of its earnings as a dividend.

Cue Biopharma quarterly revenues are $3.3M, which are smaller than FibroGen quarterly revenues of $46.3M. Cue Biopharma's net income of -$8.7M is higher than FibroGen's net income of -$17.1M. Notably, Cue Biopharma's price-to-earnings ratio is -- while FibroGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 5.40x versus 0.32x for FibroGen. Usually stocks with elevated PS ratios are considered overvalued.

GlycoMimetics has a net margin of -259.59% compared to Cue Biopharma's net margin of --. Cue Biopharma's return on equity of -142.28% beat GlycoMimetics's return on equity of --.

Cue Biopharma has a consensus price target of $4.20, signalling upside risk potential of 246.15%. On the other hand GlycoMimetics has an analysts' consensus of -- which suggests that it could grow by 323.01%. Given that GlycoMimetics has higher upside potential than Cue Biopharma, analysts believe GlycoMimetics is more attractive than Cue Biopharma.

Cue Biopharma has a beta of 1.658, which suggesting that the stock is 65.823% more volatile than S&P 500. In comparison GlycoMimetics has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.069%.

Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlycoMimetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. GlycoMimetics pays out -- of its earnings as a dividend.

Cue Biopharma quarterly revenues are $3.3M, which are larger than GlycoMimetics quarterly revenues of --. Cue Biopharma's net income of -$8.7M is higher than GlycoMimetics's net income of -$9.8M. Notably, Cue Biopharma's price-to-earnings ratio is -- while GlycoMimetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 5.40x versus -- for GlycoMimetics. Usually stocks with elevated PS ratios are considered overvalued.